Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin for Cardioprotection in Breast Cancer Patients on Doxorubicin
NCT07668076Phase 2Completed
- Sponsor
- Damanhour University
- Start
- Nov 2022
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 2, randomised trial of atorvastatin in doxorubicin-induced cardiomyopathy (2 arms), sponsored by Damanhour University. Primary endpoint: Change in serum levels of cardiac biomarkers (NT-Pro BNP, ST2 and MPO) at 3 months. Started Nov 2022; status: completed.
02
Drugs
atorvastatin
03
Conditions
doxorubicin-induced cardiomyopathy
Beyond the preview
Go deeper on NCT07668076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07668076.